e.l.f. Beauty walked into its fiscal Q4 earnings on May 20 carrying a 21% monthly drawdown, 12% short interest, and a Wall Street consensus that had spent six weeks slashing targets. The print has landed. What the data shows now tells a sharper story than the pre-event caution suggested.
Short interest came into earnings at 12.1% of the free float — elevated, but already retreating. From a mid-April peak above 8.4 million shares, the short count has fallen to roughly 7.2 million, a decline of nearly 12% over the past month. The week-over-week move is small — down about 1.8% — but the direction has been consistent since late April. Borrow costs remain negligible at 0.47%, and availability is running at 142%, well into the range where shorts face no meaningful friction. The lending market is not pressed. What's notable is that despite the stock's 21% monthly fall, shorts have been covering rather than pressing — a sign that the downside thesis was already maturing before the release.
Options traders were leaning constructive heading into the event. The put/call ratio closed at 0.70 on Tuesday, slightly below its 20-day average of 0.72 and well clear of the elevated defensive readings seen in mid-to-late April when the ratio briefly touched 0.86. That earlier caution has unwound. The ORTEX short score, meanwhile, has ticked up to 64.4 — near the high of the recent range — which reflects the combination of persistent short interest and a stock that has underperformed peers sharply. Closest correlate fell 10.3% on the week and dropped 15.4%, so the broad beauty category has been under pressure. lost 4.8% over the same period — a softer move relative to its closest peer group.
Analysts spent the past six weeks in near-uniform target-cutting mode. Morgan Stanley downgraded to Equal-Weight in early May, citing valuation. Piper Sandler slashed its target from $85 to $60 just ahead of the print, while Canaccord trimmed from $121 to $100 while keeping its Buy. The mean price target heading into earnings was $88 — a 66% premium to the $52.98 close — which reflects a Street that still broadly believes in the growth story but has lost confidence in the near-term trajectory. JPMorgan, BofA, and Citi all cut targets in April while maintaining positive ratings. The bull case centres on 91% first-half sales growth, record eye-product market share, and an easier international comparison base into the second half. The bear case is more immediate: cheek category share at a low of 31%, tough comparisons from prior high-performing launches, and FY27 sales growth estimates drifting lower. The PE multiple has compressed nearly four points over 30 days to 14.1x — a significant re-rating for a stock that traded at growth multiples through much of last year.
The earnings history adds context. February's Q3 print produced a 9.4% one-day drop and a nearly identical 9.4% loss over the following five days — a clean negative reaction with no recovery. That came despite what was widely framed as a strong growth story. The pattern suggests the market has been punishing any miss or guidance caution severely, while not rewarding beats commensurately. The insider register adds one more data point worth noting: on April 27, the CEO, CFO, COO, CMO, and two other executives all sold shares at $63.66, collectively raising over $9 million. Those sales came at a price 20% above where the stock closed this week.
The print is now in the market. What to watch is whether the post-earnings short interest reading in the coming sessions shows a further cover — which would signal the bear thesis is being retired — or a rebuild, which would indicate the result gave shorts new conviction to re-establish.
See the live data behind this article on ORTEX.
Open ELF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
